英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
coactio查看　coactio　在百度字典中的解释百度英翻中〔查看〕
coactio查看　coactio　在Google字典中的解释Google英翻中〔查看〕
coactio查看　coactio　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of . . .
    Janux is also advancing its first ARM platform clinical candidate, JANX011, a CD19-ARM for the potential treatment of autoimmune diseases in a Phase 1 study in healthy adult volunteers Janux continues to generate a number of additional TRACTr, TRACIr, and ARM programs for potential future development
  • Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of . . .
    Janux is also advancing its first ARM platform clinical candidate, JANX011, a CD19-ARM for the potential treatment of autoimmune diseases in a Phase 1 study in healthy adult volunteers
  • Janux Therapeutics Announces First Patient Dosed in Phase 1 . . . - BioSpace
    SAN DIEGO-- (BUSINESS WIRE)--Janux Therapeutics, Inc (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that the first participant has been dosed in a Phase 1 clinical study of JANX011, a CD19-targeted bispecific engineered using the company’s proprietary Adaptive Immune Response Modulator (ARM) platform
  • Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of . . .
    The Phase 1 study (NCT07291323) is an open-label, dose-escalation trial designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of JANX011 in healthy adult volunteers
  • Study of JANX011 in Healthy Adult Volunteers to Assess Safety and . . .
    This first-in-human (FIH) study aims to characterize the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of JANX011 dosed subcutaneously (and potentially intravenously) in healthy adult volunteers (HVs) to gain insight into its therapeutic utility in patients with autoimmune diseases
  • Janux | Novel T Cell Immunotherapy | CD19-ARM (JANX001)
    In February of 2026, Janux announced it dosed its first patient in a Phase 1 clinical trial in healthy volunteers CD19 is an important target for b-cell mediated diseases We designed JANX011 to drive prolonged drug free remissions as a fully off-the-shelf re-dosable therapeutic for autoimmune diseases
  • Janux Therapeutics, Inc. Announces First Patient Dosed in Phase 1 Study . . .
    Janux Therapeutics, Inc announced that the first participant has been dosed in a Phase 1 clinical study of JANX011, a CD19-targeted bispecific engineered using the company's proprietary Adaptive Immune Response Modulator (ARM) platform JANX011 is being developed for autoimmune diseases and is designed to enable deep and durable immune reset through targeted depletion of CD19-expressing B
  • Janux - Investor Relations - Press Releases - Go Daddy
    Select Year: February 26, 2026 Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights February 17, 2026 Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011 January 26, 2026 Janux Therapeutics Appoints William Go, M D , Ph D , as Chief Medical Officer
  • Janux Therapeutics Doses First Patient in Phase 1 Trial of JANX011 for . . .
    Janux Therapeutics has dosed the first participant in a Phase 1 clinical trial of JANX011, a CD19-targeted bispecific candidate designed using its ARM platfo





中文字典-英文字典  2005-2009